To determine the MTD and dose-limiting toxicities of a regimen of therapeutic ganciclovir,
antiretroviral therapy, and recombinant interleukin-2 (aldesleukin; Proleukin) as an immune
adjuvant in HIV-seropositive patients. To investigate the effect of increasing doses of
Proleukin on the time to progression of CMV retinitis in patients being treated with
therapeutic ganciclovir and antiretroviral therapy. To evaluate the incidence and level of
anti-IL-2 antibody formation to subcutaneously administered Proleukin in this patient
Patients will receive subcutaneous Proleukin in combination with ganciclovir and
antiretroviral therapy, and the MTD will be determined.
Patients must have:
Documented HIV seropositivity.
- FDA-approved antiretroviral therapy for at least 2 months prior to study entry.
- Prior G-CSF.